Spectros year-to-date third-quarter sales rose 35% over the same-period sales in 2005. This reflects growing acceptance of Tissue Oximetry in a broadening array of applications, and clinical studies showing outcome improvements. "We are pleased that physicians are now increasingly recognizing the compelling benefits of Ischemia Detection in their practices, and expect sales in Tissue Oximetry to grow considerably for the foreseeable future," comments David Benaron, CEO. Spectros is the leader in real-time noninvasive somatic molecular monitoring, such as the T-StatR 303 ischemia detection system. Devices for the real-time monitoring of breast cancer are entering Phase III trials.